Clinical Trial Update: Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of sirolimus and azacitidine in adults with high-risk myelodysplastic syndrome or acute myeloid leukemia who are recurr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Acute Myeloid Leukemia with Del
• Acute Myeloid Leukemia with Inv
• Myelodysplastic Syndromes

Drugs mentioned

• Rapamune (sirolimus)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Status: COMPLETED | Results posted: 2025-12-10